Is the ability of D-type cyclins to activate cyclin-dependent kinases an effective means of targeting these oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
- Elizabeth A. Musgrove
- C. Elizabeth Caldon
- Robert L. Sutherland
